{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:24:13Z","timestamp":1787916253385,"version":"build-2784847793"},"reference-count":101,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered to be a benign precursor condition that may progress to a lymphoproliferative disease or multiple myeloma. Most patients do not progress to an overt condition, but nevertheless, MGUS is associated with a shortened life expectancy and, in a minority of cases, a number of co-morbid conditions that include an increased fracture risk, renal impairment, peripheral neuropathy, secondary immunodeficiency, and cardiovascular disease. This review aims to consolidate current evidence for the significance of these co-morbidities before considering how best to approach these symptoms and signs, which are often encountered in primary care or within a number of specialties in secondary care.<\/jats:p>","DOI":"10.3390\/cancers12061554","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T12:16:57Z","timestamp":1592223417000},"page":"1554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Monoclonal Gammopathy of Undetermined Significance (MGUS)\u2014Not So Asymptomatic after All"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-6468","authenticated-orcid":false,"given":"Oliver C.","family":"Lomas","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrin","family":"Tahri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3816\/CLM.2009.n.002","article-title":"IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","article-title":"Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: A population-based study","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jdv.13847","article-title":"Monoclonal gammopathy of cutaneous significance: Review of a relevant concept","volume":"31","author":"Lipsker","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: A population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: A population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2141.2001.02533.x","article-title":"Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance","volume":"112","author":"Gregersen","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: A systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/bmj.38376.401701.8F","article-title":"Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: Retrospective, cross sectional study","volume":"330","author":"Abrahamsen","year":"2005","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1038\/bcj.2015.71","article-title":"Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance","volume":"5","author":"Piot","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture Risk in Monoclonal Gammopathy of Undetermined Significance","volume":"19","author":"Melton","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00223-008-9145-2","article-title":"The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance","volume":"82","author":"Pepe","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network","volume":"99","author":"Palumbo","year":"2014","journal-title":"Haematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/bloodadvances.2017010454","article-title":"Bone disease in monoclonal gammopathy of undetermined significance: Results from a screened population-based study","volume":"1","author":"Thorsteinsdottir","year":"2017","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"The International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"The International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3109\/10428194.2015.1040011","article-title":"Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both","volume":"56","author":"Zand","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41581-018-0102-7","article-title":"Publisher correction: The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2215\/CJN.06180710","article-title":"Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: A fortuitous association?","volume":"6","author":"Bridoux","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","article-title":"Dense deposit disease associated with monoclonal gammopathy of undetermined significance","volume":"56","author":"Sethi","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: A case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ckj\/sfw090","article-title":"C3 glomerulopathy in adults: A distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome","volume":"9","author":"Lloyd","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.25569","article-title":"Monoclonal gammopathy-associated thrombotic microangiopathy","volume":"94","author":"Yui","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti\u2013Factor H Autoantibodies in C3 Glomerulopathies and in atypical hemolytic uremic syndrome: One target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J. Immunol."},{"key":"ref_39","first-page":"275","article-title":"Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: Incidence, treatment and outcome","volume":"31","author":"Ye","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(12)80314-3","article-title":"Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease","volume":"20","author":"Heilman","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","article-title":"Immunoglobulin free light chains and solitary plasmacytoma of bone","volume":"108","author":"Dingli","year":"2006","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/tri.12497","article-title":"Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: A diagnostic and therapeutic challenge","volume":"28","author":"Nambirajan","year":"2014","journal-title":"Transpl. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution","volume":"7","author":"Nasr","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1016\/j.transproceed.2009.10.005","article-title":"Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: A case report","volume":"41","author":"Kaposztas","year":"2009","journal-title":"Transplant. Proc."},{"key":"ref_46","first-page":"445","article-title":"Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: A case report","volume":"14","author":"Moiz","year":"2014","journal-title":"Ochsner J."},{"key":"ref_47","first-page":"302","article-title":"Treatment with bortezomib in dense deposit disease associated with monoclonal gammopathy of undetermined significance","volume":"184","author":"Saiz","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1681\/ASN.V1271558","article-title":"Light chain deposition disease: A model of glomerulosclerosis defined at the molecular level","volume":"12","author":"Ronco","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbmt.2017.08.031","article-title":"High-dose melphalan and stem cell transplantation in patients on dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease","volume":"24","author":"Batalini","year":"2018","journal-title":"Boil. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_51","first-page":"17","article-title":"An age-calibrated definition of chronic kidney disease: Rationale and benefits","volume":"37","author":"Delanaye","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"R\u00f6gnvaldsson, S., Steingr\u00edmsson, V., Turesson, I., Bj\u00f6rkholm, M., Landgren, O., and Kristinsson, S.Y. (2020). Peripheral neuropathy and monoclonal gammopathy of undetermined significance: A population-based study including 15,351 cases and 58,619 matched controls. Haematology.","DOI":"10.1016\/j.clml.2019.09.541"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1749-6632.1971.tb13560.x","article-title":"Pathologic conditions associated with plasma cell dyscrasias: A study of 806 cases","volume":"190","author":"Isobe","year":"1971","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","article-title":"The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings","volume":"238","author":"Yeung","year":"1991","journal-title":"J. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2014.01.012","article-title":"Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy","volume":"268","author":"Stork","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/WNL.37.9.1506","article-title":"Peripheral neuropathy in macroglobulinemia: Incidence and antigen-specificity of M proteins","volume":"37","author":"Marmiroli","year":"1987","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/1531-8249(199907)46:1<119::AID-ANA18>3.0.CO;2-H","article-title":"Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy","volume":"46","author":"Meucci","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1212\/01.wnl.0000335268.70325.33","article-title":"Long-term effect of rituximab in anti-mag polyneuropathy","volume":"71","author":"Benedetti","year":"2008","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ajh.25495","article-title":"POEMS syndrome: 2019 Update on diagnosis, risk-stratification, and management","volume":"94","author":"Dispenzieri","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1212\/WNL.0000000000001565","article-title":"Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome","volume":"84","author":"Karam","year":"2015","journal-title":"Neurology"},{"key":"ref_63","first-page":"1132","article-title":"Immunoglobulin light chain amyloidosis","volume":"89","author":"Kourelis","year":"2018","journal-title":"Handb. Hematol. Malig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41590-018-0205-0","article-title":"Author Correction: The twilight of immunity: Emerging concepts in aging of the immune system","volume":"19","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: A population-based study","volume":"97","author":"Kristinsson","year":"2011","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections","volume":"47","author":"Brandhorst","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the united kingdom medical research council trials between 1980 and 2002\u2014Medical research council adult leukaemia working party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_70","first-page":"79","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Vidriales","year":"2012","journal-title":"Haematology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00021-11","article-title":"Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance","volume":"18","author":"Karlsson","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0264-410X(98)00117-0","article-title":"Immune response to influenza vaccination in a large healthy elderly population","volume":"17","author":"Bernstein","year":"1999","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.exphem.2015.02.005","article-title":"Monoclonal paraprotein influences baseline B-cell repertoire diversity and perturbates influenza vaccination-induced B-cell response","volume":"43","author":"Tete","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.V114.22.1852.1852","article-title":"Lack of response to vaccination in MGUS and stable myeloma","volume":"114","author":"Prabhala","year":"2009","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2017.02.025","article-title":"Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: A prospective, single-arm trial","volume":"17","author":"Branagan","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2147\/CIA.S220423","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance\u2014Relationship with selected immune and clinical parameters","volume":"14","author":"Pasiarski","year":"2019","journal-title":"Clin. Interv. Aging"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(00)04237-9","article-title":"Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: A prospective study","volume":"357","author":"Christenson","year":"2001","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/CVI.00654-15","article-title":"Poor correlation between pneumococcal IgG and IgM titers and opsonophagocytic activity in vaccinated patients with multiple myeloma and waldenstrom\u2019s macroglobulinemia","volume":"23","author":"Karlsson","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_81","first-page":"748","article-title":"Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"Dhalla","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_82","first-page":"440","article-title":"Room for improvement: Immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia","volume":"12","author":"Shanafelt","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_83","first-page":"1","article-title":"Vaccination of oncology patients: An effective tool and an opportunity not to be missed","volume":"17","author":"Kotton","year":"2012","journal-title":"Oncology"},{"key":"ref_84","first-page":"53","article-title":"Multiple myeloma vaccination patterns in a large health system: A pilot study","volume":"4","author":"Alemu","year":"2017","journal-title":"J. Patient-Cent. Res. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdh385","article-title":"The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance","volume":"15","author":"Sallah","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.thromres.2009.01.004","article-title":"The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease","volume":"125","author":"Cohen","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.2010.01539.x","article-title":"Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism","volume":"86","author":"Gregersen","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3816\/CLM.2007.n.027","article-title":"Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders","volume":"7","author":"Auwerda","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00277-019-03786-9","article-title":"How to resolve a clinical and molecular puzzle: Concomitant monoclonal gammopathy of undetermined significance (MGUS) with neutrophilia and clonal hematopoiesis of indeterminate potential (CHIP)","volume":"98","author":"Haefliger","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Mouhieddine, T.S., Redd, R.A., Park, J., Leventhal, M., Gibson, C., Manier, S., Nassar, A., Capelletti, M., Huynh, D., and Bustoros, M.W. (2020). Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat. Commun., in press.","DOI":"10.1038\/s41467-020-16805-5"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/leu.2015.336","article-title":"Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: Estimating the burden on health care","volume":"30","author":"Go","year":"2015","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_100","unstructured":"(2020, April 13). ClinicalTrials.gov. Identifier NCT03327597, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03327597."},{"key":"ref_101","unstructured":"(2020, April 13). ClinicalTrials.gov. Identifier NCT03689595, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03689595."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:16Z","timestamp":1760175496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":101,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061554"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061554","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}